

## **Abattis Announces Renewal of Health Canada Licence**

Vancouver, BC – November 7, 2016 - Abattis Bioceuticals Corp. (the "**Company**" or "**Abattis**") (OTCQB: ATTBF) (CSE: ATT), announces the renewal of the Health Canada Licence for the Northern Vine Canada Inc. testing lab.

Health Canada has confirmed the renewal of the Langley, BC facility's controlled substances testing licence. The Company has fulfilled Health Canada's rigorous specifications, and successfully completed all thorough inspections. Accordingly, the lab has received its controlled substances licence renewal for the 2017 year.

The Company has worked hard to meet the requirements within Health Canada's strictly regulated licensing environment. It is a testament to the professionalism of the team that has maintained the high standards of safety, quality and security in accordance with Health Canada's regulations governing controlled substances testing facilities. This is an annual requirement and a big step toward Abattis entering the revenue stage for its shareholders.

### **About Abattis Bioceuticals Corp.**

Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company also is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: [www.abattis.com](http://www.abattis.com).

### **About Northern Vine Canada Inc.**

Northern Vine Labs™ is licensed by Health Canada for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the Canadian market.

### **About Vergence Visionary Bioceuticals Corp.**

Vergence Visionary Bioceuticals, dba Vergence Sales and Marketing Group, is a wholly owned subsidiary of Abattis Bioceuticals Corp. based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast growing market for natural, safe and effective natural products that meet unmet wellness needs.

ON BEHALF OF THE BOARD

*"Rene David"*

Rene David, CFO, Acting CEO

For further information, contact the Company at (604) 336-0881 or at [news@abattis.com](mailto:news@abattis.com).

**FORWARD LOOKING INFORMATION**

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on [www.sedar.com](http://www.sedar.com). While the Company may elect to, it does not undertake to update this information at any particular time. ***NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.***